GSK Entered into an Exclusive Licence Agreement and SCYNEXIS to Develop and Commercialise Brexafemme (ibrexafungerp) for Fungal In...
Shots: SCYNEXIS to receive $90M up front, $503M in milestones incl. ~$70M in regul...
Shots: SCYNEXIS to receive $90M up front, $503M in milestones incl. ~$70M in regul...
Shots: Confo to receive up front & is eligible to receive development and comm...
Shots: Galimedix will receive an up front technology access fee, success-based mil...
Shots: Covant to receive $10M up front and will be eligible for ~$471M in addition...
Shots: Bicycle to receive a $50M up front, ~$1.7B in development & commercial-...
Shots: OncoVent to receive a total transaction amount of $11.2M incl. a one-off no...
Incisive News in 3 Shots.